THE SAFETY OF MESENCHIMAL STROMAL CELLS THERAPY

Autor:	A A Churikova, A A Lishinskaya, N A Fadeeva, A I Parfenov, E Yu Bondarenko, A. G. Konoplyannikov, E A Albulova, A V Kagramanova, O N Boldyreva, I N Ruchkina, S V Bykova, Oleg Knyazev
Rok vydání:	2014
Předmět:	Oncology Crohn's disease medicine.medical_specialty Stromal cell business.industry Proliferative capacity Immunogenicity Mesenchymal stem cell medicine.disease Ulcerative colitis Inflammatory bowel disease Cell therapy Internal medicine medicine business
Zdroj:	Journal of Clinical Practice. 5:5-14
ISSN:	2618-8627 2220-3095
DOI:	10.17816/clinpract535-14
Popis:	There is a large amount of literature data that shows the effectiveness of cell therapy using mesenchymal stromal cells (MSCs), as on preclinical models and in some clinical studies in small groups of patients.Currently the use of MSC in clinical practice is limited by security considerations. Potential risks associated with their proliferative capacity, the risk of infectious complications, as well as the possible immunogenicity of the cells themselves.Foreign researchers analyzed on the basis of a literature review, the results of which evaluated the clinical safety of MSCs. The article presents the results of our monitoring of patients with inflammatory bowel disease (IBD), which received MSCs in the Department of pathology bowel. The results of our study, and the results, given in the review, should provide scientists and policy-makers the confidence that according to available scientific data an innovative method of cell therapy is safe for clinical use.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::19e0c03cce576ff6b97f75e617712325 https://doi.org/10.17816/clinpract535-14 Zobrazit plný text záznamu